These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22437507)

  • 1. Temozolomide dosing regimens for glioma patients.
    Strik HM; Marosi C; Kaina B; Neyns B
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):286-93. PubMed ID: 22437507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New (alternative) temozolomide regimens for the treatment of glioma.
    Wick W; Platten M; Weller M
    Neuro Oncol; 2009 Feb; 11(1):69-79. PubMed ID: 18772354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rechallenge with temozolomide in recurrent glioma.
    Gaviani P; Silvani A; Lamperti E; Botturi A; Fariselli L; Simonetti G; Ferrari D; Salmaggi A
    Neurol Sci; 2011 Nov; 32 Suppl 2():S247-9. PubMed ID: 21987286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
    Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
    J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of temozolomide on immune response during malignant glioma chemotherapy.
    Sengupta S; Marrinan J; Frishman C; Sampath P
    Clin Dev Immunol; 2012; 2012():831090. PubMed ID: 23133490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
    Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
    Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal role of temozolomide in the treatment of malignant gliomas.
    Stupp R; van den Bent MJ; Hegi ME
    Curr Neurol Neurosci Rep; 2005 May; 5(3):198-206. PubMed ID: 15865885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
    Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
    Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of temozolomide in recurrent malignant gliomas.
    Gaya A; Rees J; Greenstein A; Stebbing J
    Cancer Treat Rev; 2002 Apr; 28(2):115-20. PubMed ID: 12297119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
    Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
    J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of temozolomide treatment for patients with glioma.
    Yang WB; Xing BZ; Liang H
    Asian Pac J Cancer Prev; 2014; 15(19):8405-8. PubMed ID: 25339037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.
    Ezaki T; Sasaki H; Hirose Y; Miwa T; Yoshida K; Kawase T
    Mol Med Rep; 2011; 4(6):1101-5. PubMed ID: 21874248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide in malignant gliomas: current use and future targets.
    Villano JL; Seery TE; Bressler LR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
    Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
    Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
    van Vugt VA; Piccioni DE; Brown BD; Brown T; Saria MG; Juarez T; Kesari S
    CNS Oncol; 2014 Jul; 3(4):257-65. PubMed ID: 25286037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.